Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H21ClN2O8.C7H6O6S |
| Molecular Weight | 695.048 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(O)C=CC(=C1)S(O)(=O)=O.CN(C)[C@H]2[C@@H]3[C@@H](O)[C@@H]4C(=C)C5=C(Cl)C=CC(O)=C5C(=O)C4=C(O)[C@]3(O)C(=O)C(C(N)=O)=C2O
InChI
InChIKey=FYSVKUUNXYGFLA-CCHMMTNSSA-N
InChI=1S/C22H21ClN2O8.C7H6O6S/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30;8-6-2-1-4(14(11,12)13)3-5(6)7(9)10/h4-5,10,14-15,17,26,28-30,33H,1H2,2-3H3,(H2,24,32);1-3,8H,(H,9,10)(H,11,12,13)/t10-,14-,15+,17+,22+;/m1./s1
| Molecular Formula | C22H21ClN2O8 |
| Molecular Weight | 476.864 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C7H6O6S |
| Molecular Weight | 218.184 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Meclocycline is a tetracycline antibiotic. It is used topically for skin infections treatment. Tetracyclines are broad-spectrum bacteriostatic agents and act by inhibiting protein synthesis by blocking the binding of aminoacyl tRNA (transfer RNA) to the mRNA (messenger RNA) ribosome complex. Meclocycline might increase sensitivity to light when it is used with Aminolevulinic acid.
Originator
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 12-37 |
Other AEs: Yellow skin... |
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy |
Other AEs: Contact dermatitis... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Yellow skin | 6% | 1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 12-37 |
| Contact dermatitis | 1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Noticeable improvement may be seen in 4 to 6 weeks. In some patients it may require up to 6 to 8 weeks of treatment before noticeable improvement is seen and up to 8 to 12 weeks before maximum benefit is seen.
Two times a day, morning and evening.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:51:51 GMT 2025
by
admin
on
Mon Mar 31 17:51:51 GMT 2025
|
| Record UNII |
46VZA7RX2B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1595
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1377508
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
DBSALT002414
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
46VZA7RX2B
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
73816-42-9
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL261772
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
C47596
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
SUB03105MIG
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
DTXSID5045596
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
277-614-2
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
100000086163
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
757831
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | |||
|
203162
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | RxNorm | ||
|
m7119
Created by
admin on Mon Mar 31 17:51:51 GMT 2025 , Edited by admin on Mon Mar 31 17:51:51 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |